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Crystal structure of acivicin-inhibited γ-glutamyltranspeptidase
reveals critical roles for its C-terminus in autoprocessing and
catalysis.*
Kristin Williams, Sierra Cullati, Aaron Sand, Ekaterina I. Biterova, and Joseph J. Barycki
Department of Biochemistry, University of Nebraska, 1901 Vine Street, Lincoln, Nebraska
68588-0664
Abstract
Helicobacter pylori γ-glutamyltranspeptidase (HpGT) is a general γ-glutamyl hydrolase and a
demonstrated virulence factor. The enzyme confers a growth advantage to the bacterium, providing
essential amino acid precursors by initiating the degradation of extracellular glutathione and
glutamine. HpGT is a member of the N-terminal nucleophile (Ntn) hydrolase superfamily and
undergoes autoprocessing to generate the active form of the enzyme. Acivicin is a widely used γ-
glutamyltranspeptidase inhibitor that covalently modifies the enzyme, but its precise mechanism of
action remains unclear. The time-dependent inactivation of HpGT exhibits a hyperbolic dependence
on acivicin concentration with kmax = 0.033 ± 0.006 sec−1 and KI = 19.7 ± 7.2 μM. Structure
determination of acivicin-modified HpGT (1.7 Å; Rfactor=17.9%; Rfree=20.8%) demonstrates that
acivicin is accommodated within the γ-glutamyl binding pocket of the enzyme. The hydroxyl group
of Thr 380, the catalytic nucleophile in the autoprocessing and enzymatic reactions, displaces
chloride from the acivicin ring to form the covalently linked complex. Within the acivicin-modified
HpGT structure, the C-terminus of the protein becomes ordered with Phe 567 positioned over the
active site. Substitution or deletion of Phe 567 leads to a >10-fold reduction in enzymatic activity,
underscoring its importance in catalysis. The mobile C-terminus is positioned by several electrostatic
interactions within the C-terminal region, most notably a salt bridge between Arg 475 and Glu 566.
Mutational analysis reveals that Arg 475 is critical for the proper placement of the C-terminal region,
the Tyr 433 containing loop, and the proposed oxyanion hole.
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H. pylori γ-glutamyltranspeptidase (HpGT) is a γ-glutamyl hydrolase with broad substrate
specificity (1,2), and is a member of the N-terminal nucleophile (Ntn) hydrolase superfamily
(3,4). The inactive precursor undergoes an intramolecular autoprocessing event, generating the
mature and catalytically active heterotetramer. A conserved threonine residue, Thr 380, serves
as the N-terminal nucleophile and is required for both maturation and enzymatic activity (1).
HpGT has been shown to degrade extracellular glutathione and glutamine, providing a growth
advantage to the bacterium within its microenvironment (2,5,6). Similarly, upregulation of
human γ-glutamyltranspeptidase in cancer is thought to help supplement these rapidly dividing
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cells with essential amino acid precursors for glutathione and protein biosynthesis (7,8). In
mammalian systems, γ-glutamyltranspeptidase has been shown to be critical for the transport
of cysteine for use in protein and glutathione biosynthesis (9,10). The enzyme is required for
normal glutathione metabolism, initiating extracellular glutathione degradation. Subsequent
steps lead to the cellular uptake of the composite amino acids of glutathione: glutamate,
cysteine, and glycine (11,12).
Acivicin is a commonly used mechanism-based inhibitor of γ-glutamyltranspeptidases (13,
14), although its precise mechanism of action has not been determined. Structurally, it
resembles the γ-glutamyl group of known substrates of γ-glutamyltranspeptidases (Figure 1),
and is predicted to react with the catalytic nucleophile of the enzyme. Previous studies by
Meister and co-workers suggested that the site of reactivity is a hydroxyl group near the active
site of the enzyme (15–17). Specifically, Thr 523 of the rat enzyme was covalently modified
by the inhibitor (17), whereas Ser 406 of the human homologue was labeled (15). However,
mutational analysis of the human enzyme, which shares nearly 80% sequence identity with rat
γGT, indicated that neither Thr 524 (equivalent to Thr 523 of the rat enzyme) nor Ser 406 was
required for enzymatic function (15). Furthermore, recent structural studies indicate that both
residues are relatively far removed from the active site of the enzyme (18,19).
To reconcile these inconsistencies, a comprehensive examination of the inhibition of HpGT
by acivicin was conducted. The kinetics of acivicin inhibition and the structure of the inhibited
form of HpGT were determined. The data indicate that acivicin is accommodated within the
γ-glutamyl binding pocket of the enzyme, with the catalytic nucleophile, Thr 380, as the site
of covalent modification. The structure of the acivicin-modified HpGT also reveals residues
within the C-terminal region of the protein that are critical for autoprocessing and/or catalysis.
MATERIALS AND METHODS
Expression and purification of wild-type and mutant HpGT
The preparation of HpGT has been described previously (1,2). Briefly, recombinant HpGT
was expressed in E. coli and purified from the soluble lysate by affinity chromatography using
a nickel-chelating column (Novagen). Point mutations were introduced at residues R175, R475,
R502, R513, E515, and F567 of the standard expression construct using the QuikChange site-
directed mutagenesis kit (Stratagene) following the manufacturer’s protocol. For mutant
proteins incapable of maturation, the equivalent substitutions were generated in a bicistronic
HpGT expression construct (HpGT-Duet) designed to generate mature enzyme independently
of self-processing. All constructs were verified by sequencing (Genomics Core at the
University of Nebraska-Lincoln).
Kinetic characterization of wild-type and mutant HpGT
Apparent kinetic constants for the autoprocessing of the HpGT precursor and the hydrolysis
of the substrate analogue, L-glutamic acid γ-(4-nitroanilide) (GNA; Sigma) by mature HpGT
were determined as described previously (1,20). To examine the efficacy of acivicin ((αS, 5S)-
α-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid; Sigma) as a mechanism-based
inhibitor, wild-type HpGT (0.1 mg/ml) was incubated in 20 mM Tris buffer, pH 7.4, at 4 °C
with various concentrations of the inhibitor (5–30 μM). At the indicated time, an aliquot was
removed and enzymatic activity was measured by monitoring the hydrolysis of GNA using a
Cary 50 spectrophotometer (0.1 M Tris buffer, pH 8.0; 1 mM GNA; 25 °C). To investigate the
effect of a protein ligand on the rate of inactivation, HpGT was preincubated with 1 mM
glutamate prior to the addition of 10 μM acivicin. Data were plotted as a function of time and
fit to a single-order decay with Prism (Graph Pad Software). Representative data from three
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or more determinations are presented with experimental errors determined from individual fits
of the kinetic data.
Generation of the refined acivicin-modified HpGT structure
Wild-type HpGT crystals were grown as described previously (19). Prior to data collection,
crystals were transferred to artificial mother liquor containing 30% polyethylene glycol 2000
monomethyl ether and 1 mM acivicin, a mechanism-based inhibitor of γ-
glutamyltranspeptidase. The crystals were incubated in this solution for approximately ten
minutes and then flash frozen in liquid nitrogen. Diffraction data (λ=0.9 Å; 100 K) were
collected on Beamline 14-BM-C of BioCARS at Argonne National Laboratory’s Advanced
Photon Source and analyzed using the HKL2000 software package (21). Wild-type HpGT
apoenzyme (PDB ID 1NQO) was used as the initial model (19), and iterative rounds of model
building and refinement were performed using the programs COOT (22) and REFMAC5
(23), respectively. An Rfree test set (10%) was maintained to monitor refinement, and TLSMD
(24) was used to identify optimal multi-group TLS models for use in REFMAC (25). The
acivicin-modified threonine residue was built in the Monomer Sketcher Library module of the
CCP4 software package (26). As discussed below, both the sp3 and sp2-hybridization of C3 of
acivicin were initially considered but ultimately the sp2-hybridization was chosen for
subsequent refinement. Water molecules obeying proper hydrogen-bonding constraints with
electron densities greater than 1.0 σ on a 2Fo–Fc map and 4.0 σ on an Fo–Fc map were also
included in the final structure. Model geometry was monitored using MOLPROBITY (27) and
figures were produced using Chimera (28).
RESULTS AND DISCUSSION
Inactivation of HpGT by acivicin
Incubation of HpGT with 10 μM acivicin at pH 7.4 and 4 °C resulted in a time-dependent
inactivation of the enzyme (Figure 2A, squares), whereas the enzyme alone exhibited no loss
of activity over the indicated time frame (data not shown). The inclusion of glutamate (1 mM;
Figure 2A, triangles), a product of the hydrolysis reaction, resulted in an approximately 6-fold
reduction in the inactivation rate (0.011 ± 0.001 sec−1 versus 0.002 ± 0.001 sec−1), suggesting
that the acivicin binding site is coincident with the γ-glutamyl binding site. HpGT was
incubated with various amounts of acivicin (5–30 μM) to determine the dependence of the rate
of inactivation on reagent concentration (Figure 2B). The observed rate constants exhibited a
hyperbolic dependence on the acivicin concentration, suggesting the formation of an enzyme-
inhibitor complex prior to covalent modification. The observed rate constant (kobs) at a
particular reagent concentration (R) can be described by
where kmax is equal to the maximal inactivation rate at saturating concentrations of the reagent
and KI= (k−1 + kmax)/k1 and represents the reagent concentration that results in half of the
maximal inactivation rate (29). The double-reciprocal plot (Figure 2B, inset) was used to
calculate kmax = 0.033 ± 0.006 sec−1 and KI = 19.7 ± 7.2 μM.
Identification of Threonine 380 as the site of modification by acivicin
Structural studies were conducted to determine the mode of inhibition by acivicin. Wild-type
HpGT crystals were transferred to artificial mother liquor containing 1mM acivicin, incubated
for approximately 10 minutes, and flash frozen in liquid nitrogen. HpGT has been shown to
be enzymatically active in the crystal lattice (20) and X-ray diffraction data were collected to
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a resolution of 1.7 Å (Table 1). A complete heterotetramer (2 large subunits, 2 small subunits)
is contained within the asymmetric unit. Chains A and C correspond to the large subunits
(residues 31 through 372 and 32 through 379, respectively), whereas chains B and D identify
the small subunits (residues 380 through 567). The refined model has an overall Rfactor=17.9%
(Rfree=20.8%) with >97% of all residues in the favored region of the Ramachandran plot
(27). Prior to inclusion of Thr 380 and acivicin in the model, continuous electron density,
corresponding to covalently attached inhibitor, was observed in the active site of the enzyme
(Figure 3). A careful examination of the electron density map did not indicate the presence of
a second site of modification. Electrospray mass spectrometry (University of Nebraska Mass
Spectrometry Facilty) was used to confirm that only the small subunit of HpGT was modified
by acivicin with an apparent 1:1 stoichiometry (data not shown).
An examination of the final model indicates that HpGT binds acivicin and glutamate in similar
orientations (Figure 4). The structurally equivalent carboxylate and amino groups of bound
glutamate and acivicin adopt nearly identical conformations and form comparable hydrogen
bonds with the enzyme. The active site of HpGT readily accommodates the dihydroisoxazole
ring of acivicin, which superimposes reasonably well with the glutamate side chain. In the
covalent complex, the chlorine of acivicin has been displaced by the nucleophilic attack of the
Thr 380 hydroxyl group, the catalytic nucleophile in both the autoprocessing and hydrolysis
reactions. Interestingly, two alternate conformations of the covalently modified Thr 380 are
observed. In one heterodimer (chain ids A and B), Thr 380 adopts a conformation similar to
that observed for the HpGT-glutamate product complex (Figure 4A). Its amino terminal group
is within hydrogen bond distance of a structurally conserved water molecule, the backbone
carbonyl oxygen of Asn 400, and the side chain oxygen of Thr 398. In the second heterodimer
(chain ids C and D), the Thr 380 amino group has rotated approximately 90 degrees, disrupting
its interaction with Asn 400 and forming a new hydrogen bond with the backbone carbonyl
oxygen of Tyr 397 (Figure 4B). The functional significance of this alternate Thr 380
conformation is not evident from the current studies. However, this observation suggests that
Thr 380 may adopt alternate conformations during maturation and catalysis. These structural
changes may impact the pKa of the α-amino group of Thr 380 and allow it to serve as a general
base during catalysis.
Previous studies with mammalian γ-glutamyltranspeptidases suggested that acivicin reacts
with a hydroxyl group within the 20 kDa subunit. For human γGT, the site of modification was
identified as Ser 406 (15) whereas Thr 523 was modified in rat γGT (17). The equivalent
residues in HpGT, Ser 405 and Lys 524, are more than 14 Å and 26 Å, respectively, from the
reactive center of bound acivicin, and there is no evidence for their modification within the
electron density maps. This observation suggests that the previously identified targets of
acivicin modification likely represent secondary sites of reactivity. Although it is possible that
there are structural differences between HpGT and mammalian γGT that may account for the
observed differences, recent studies using the related mechanism-based inhibitor, 2-amino-4-
[mono(4-cyanophenyl)phosphono]butanoic acid (30,31), demonstrated the N-terminal
threonine residue of human γGT, Thr 381, is clearly modified (32). Furthermore, replacement
of either Thr 524 or Ser 406 with an alanine residue in human γGT had no impact on enzymatic
activity, indicating that neither residue is directly involved in substrate binding and catalysis.
Recently, the structure of acivicin-modified E. coli γGT was reported and Thr 391, equivalent
to Thr 380 in HpGT, was identified as the site of modification (33). The E. coli and the H.
pylori structures were determined to similar resolutions (1.65 Å and 1.7 Å respectively) and
are comparable with respect to the overall acivicin binding site (Figure 3). However,
dissimilarities with respect to the dihydroisoxazole ring are evident. In the HpGT structure,
the dihydroisoxazole ring is nearly perpendicular to that observed in the E. coli structure. This
orientation allows the N2 nitrogen of acivicin to interact directly with the backbone amides of
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Gly 472 and Gly 473 in HpGT. In E. coli γGT, a bridging water molecule is required to interact
with the backbone amide of Gly 483 (33). In addition, the hybridization at C3, the site of
attachment to the Oγ of the catalytic threonine, is markedly different. In the E. coli structure,
the Oγ of Thr 391 is significantly out of plane with respect to the dihydroisoxazole ring,
suggesting that C3 is sp3-hybridized. In acivicin-modified HpGT, the Oγ of Thr 380 is co-
planar with respect to the dihydroisoxazole ring, indicating that C3 is likely sp2-hybridized.
These observed differences are significant with respect to the precise mechanism of
modification.
Largely based on the unexpected sp3 geometry for C3 in E. coli γGT, the authors proposed an
unusual inactivation mechanism that would require the oxygen-nitrogen bond of the
dihydroisoxazole ring to break and reform, resulting in a net migration of a double bond from
N2-C3 to C4-C5 (33). Such a mechanism would likely be facilitated by the presence of a general
base near C4 and C5, however the identity of such a functional group is not readily apparent
in the E. coli γGT structure. In contrast, the observed sp2 geometry for C3 in the HpGT structure
is consistent with simple chloride displacement from acivicin by Thr 380 and maintenance of
the dihydroisoxazole ring, analogous to the mechanism proposed for the acivicin mediated
inactivation of carbamoyl phosphate synthetase (34). The nucleophilic attack of Thr 380 Oγ
on C3 of acivicin would be facilitated by the backbone amides of Gly 472 and Gly 473, which
would stabilize the developing negative charge on N2. Collapse of the tetrahedral intermediate
would then lead to displacement of the chloride ion. Confidence in the assigned sp2 geometry
for the HpGT structure is considerable, as attempts to model C3 of acivicin with an sp3
geometry resulted in several significant difference peaks around the Thr 380 Oγ - C3 bond
(data not shown). Given that mature HpGT and E. coli γGT share >50% sequence identity and
maintain nearly identical active site architectures, it is unlikely that acivicin modification would
proceed via different mechanisms.
The C-terminus of HpGT contributes to formation of the active site
In previously described HpGT structures, the final three residues of the 20 kDa subunit were
not visible within the electron density maps and were not included in the final models.
Modification of HpGT with acivicin leads to ordering of Lys 565, Glu 566, and Phe 567 (Figure
5A), with Phe 567 positioned proximal to the substrate binding site and adjacent to Thr 380,
the site of acivicin modification (Figure 5B). Removal of the benzyl ring (F567A) or the entire
residue (F567Stop) results in an approximately 12-fold reduction in enzymatic activity (Table
2) without significantly impacting either Km or the rate of autoprocessing. These observations
suggest that the bulky ring of Phe 567 may occlude solvent access to the active site and facilitate
catalysis in a fashion similar to Tyr 433. Previously, we have shown that Tyr 433 is located on
a mobile loop that clamps down over the substrate, forming a wall of the active site (20).
Similarly, the Y433A mutant had approximately 25-fold less activity with no significant impact
on Km or autoprocessing.
As with the mobile loop containing Tyr 433, the C-terminus of the 20 kDa subunit is positioned
by several hydrogen bonds (Figure 5). The side chain of Arg 175 forms hydrogen bonds with
the backbone carbonyls of Lys 565 and Glu 566. The backbone amide nitrogen of Arg 175 also
interacts via a water molecule with the ε amino group of Lys 565. Substitution with a leucine
(R175L) results in a comparable ~7-fold reduction in catalytic activity with no adverse effects
on substrate binding or enzyme maturation (Table 2). In addition, Glu 566 can form hydrogen
bonds directly and through a bound water molecule with Arg 475 as well as the backbone amide
of Gly 541. As will be discussed below, disruption of these interactions dramatically reduces
enzymatic activity.
Although the C-terminus of HpGT is clearly contributing to the overall enzymatic efficiency
of the enzyme, this region of the protein exhibits low sequence conservation. Representative
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γGT sequences corresponding to the C-terminal region are aligned in Figure 6. Asp 562 and
Arg 564 are highly conserved across numerous species but beyond these two residues,
considerable sequence variability exists. Although a general trend towards an aromatic residue
at the ultimate C-terminus is observed, structural alignment of E. coli γGT and HpGT indicates
that it is unlikely this residue is positioned similarly in all γGT (Figure 6A). Overall, the two
structures are highly homologous and maintain similar positions for Asp 562 and Arg 564
(Asp569 and Arg 571 in E. coli γGT). However, the C-terminus of HpGT extends into the
active site with Phe 567 in close proximity to the catalytic nucleophile, whereas the C-terminus
of E. coli γGT loops out of the active site towards the surface of the protein (Figure 6A). Thus
the C-terminal capping of the HpGT active site may be a unique structural feature of this
enzyme that could be exploited in the design of HpGT selective inhibitors.
Arginine 475 is required for proper placement of the Tyr 433 loop and the C-terminal tail of
HpGT
As indicated above, Glu 566 is positioned in part through interactions with Arg 475 and likely
stabilizes the C-terminus of the 20 kDa subunit. Both residue positions are highly variable,
although Arg 475 is located in a GXXGGXXI motif that is remarkably conserved within the
γGT family (residues 469–476). Gly 472 and Gly 473 of this motif form the oxyanion hole that
stabilizes the transition state of the reaction (Figures 3 and 4A). Arg 475, via bridging water
molecules, also interacts with the backbone carbonyls of Leu 432 and Tyr 433 of the active
site loop (Figure 7A). To examine the importance of this residue, a leucine mutant was
generated (R475L; Table 2). This substitution resulted in a >80-fold reduction in enzymatic
activity without impacting autoprocessing and illustrates the central role of this residue in
catalysis. In addition, the R475L mutant exhibits an ~8-fold reduction in Km suggesting that
the local substrate binding environment is also affected by disruption of the Arg 475
interactions. These observed kinetic differences indicate that Arg 475 is important for the
proper positioning of Phe 567 and Tyr 433, which work in concert to exclude bulk solvent
from the HpGT active site. In addition, these interactions likely lead to optimal formation of
the oxyanion hole. Additional mutational analyses and pre-steady state kinetic studies to
delineate the individual contributions of the Tyr 433 loop, the C-terminal cap, and Arg 475 to
catalysis are ongoing.
Disruption of conserved salt-bridges in the C-terminal region of the 20 kDa subunit
significantly impairs autoprocessing and hydrolase activities
As noted above, Asp 562 and Arg 564 are conserved among γGT family members (Figure 6A).
An examination of the HpGT structure indicates that the carboxylate of Asp 562 interacts with
Arg 564 as well as another conserved arginine residue, Arg 502 (Figure 7B). Similarly, Arg
564 forms a salt bridge with a conserved glutamate residue, Glu 515. Given the extensive
hydrogen bond network involving these residues and their remote location relative to the
catalytic nucleophile (>12 Å), it is likely that these four highly conserved residues have a
structural role. To test this possibility, the Glu 515/Arg 564 and the Arg 502/Asp 562 salt
bridges were disrupted by site directed mutagenesis. The isosteric E515Q substitution
abolished processing, indicating that strict conservation of the electrostatic character as well
as the ability to form hydrogen bonds is required for autoprocessing (Table 2). Substitution of
Arg 502 with a leucine (R502L) similarly abolished maturation of the protein (Table 2).
Importantly, both mutants were expressed in the soluble fraction and were stable at 37 °C for
> 14 days (data not shown), suggesting that gross disruption of protein structure does not occur
as a result of these substitutions.
To test the importance of the Glu 515/Arg 564 and the Arg 502/Asp 562 salt bridges in catalysis,
mature E515Q and R502L mutants were generated using a bicistronic HpGT expression
system. Using this system, an N-terminal histidine tag is incorporated into the 40 kDa subunit
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and coexpressed with the untagged 20 kDa subunit. Both the E515Q-Duet and the R502L-Duet
mutants were expressed in the soluble fraction as an intact heterotetramer, suggesting that the
amino acid substitutions do not dramatically impact protein structure. Strikingly, both E515Q-
Duet and the R502L-Duet mutants exhibited kinetic constants comparable to the mature R475L
mutant. Vmax values for E515Q-Duet and R502L-Duet were reduced >200-fold and >80-fold
relative to wild-type HpGT, respectively. Similar 6 to 8-fold reductions in Km were also
observed. To further probe the structural significance of this region, a third mutant, R513L was
constructed. Arg 513 is not a conserved residue but is located within the loop connecting Arg
502 and Glu 515, next to Arg 475 (Figure 7B). The R513L mutant exhibited an intermediate
phenotype, with a ~5-fold reduction in processing rate and a ~20-fold reduction in Vmax. As
both Glu 515 and Arg 502 are considerably removed from the active site, these results are
consistent with a structural role for these two residues. Disruption of Glu 515/Arg 564 and the
Arg 502/Asp 562 salt bridges likely impacts local protein structure and/or dynamics, negatively
impacting autoprocessing and enzymatic activity.
In summary, the structure of acivicin-modified HpGT is consistent with the nucleophilic attack
of Thr 380 Oγ at C3 of acivicin and the displacement of chloride. In contrast to the inactivation
of E. coli γGT (33), the integrity of the dihydroisoxazole ring is likely maintained during the
reaction, as C3 retains its sp2 hybridization. The unique C-terminal capping of the active site
we observed within the acivicin-modified HpGT structure, coupled with our mutagenesis
studies, demonstrates that Phe 567 contributes to the overall catalytic efficiency of the enzyme.
Further examination of the contributions of residues within the C-terminal domain of the 20
kDa subunit indicate that local structural motifs are critical for optimal enzymatic activity and
autoprocessing. These new insights into HpGT structure and function relationships will
facilitate the design of selective γGT inhibitors.
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Figure 1.
Comparison of glutathione and acivicin structures.
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Figure 2. Inactivation of HpGT by acivicin
(A) HpGT (0.1 mg/ml) was incubated with 10 μM acivicin at pH 7.4 and 4 °C in the absence
(squares) and presence (triangles) of 1 mM glutamate. The kobs for the reactions were
determined from the slope of ln(Et/Eo) versus time, where Eo and Et are the enzymatic activities
at time 0 and time t respectively. (B) Dependence of the rate of HpGT inactivation on acivicin
concentration. HpGT was incubated with various concentrations of acivicin and the rate of
inactivation determined as in Panel A. (Inset) Double reciprocal plot used to calculate kmax
and KI.
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Figure 3. Electron density corresponding to the site of acivicin modification
The refined model of acivicin-modified HpGT with pertinent active site residues is shown in
stick representation and is superimposed with acivicin-modified E.coli γGT. Oxygen atoms
are shown in red and nitrogen atoms in blue. Carbon atoms are colored green in HpGT, grey
in acivicin, and blue in E.coli γGT. Residue numbers are noted in black (HpGT) and blue
(E.coli γGT). Also shown are the calculated electron density maps after the initial round of
refinement, prior to inclusion of Thr 380 and acivicin in the model. The relevant 2Fo-Fc electron
density is contoured at 1.0 σ and illustrated in black. Positive and negative peaks in the
difference map, contoured at 3.0 σ, are shown in blue and red respectively. Potential hydrogen
bonds were identified with Chimera and are indicated as solid black lines.
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Figure 4. Alternate conformations of Thr 380 following acivicin modification
Crystals of acivicin-modified HpGT contain a heterotetramer within the asymmetric unit, and
provide two separate active site models. The active site regions of the refined structure are
colored as in Figure 3. For reference, Thr 380 and bound glutamate from the previously
determined HpGT-glutamate complex (blue) have been superimposed (20). The
dihydroisoxazole ring of acivicin superimposes reasonably well with the glutamate side chain,
and nearly identical placements of active site residues are observed with the exception of the
slight displacement of Thr 380. (A) Within one active site, formed by the A and B subunits of
the heterotetramer, Thr 380 adopts a conformation comparable to previous HpGT structures,
with its α-amino group within hydrogen bond distance to the backbone carbonyl group of Asn
400, the hydroxyl group of Thr 398, and a tightly bound water molecule. (B) In the second
active site comprised of subunits C and D, Thr 380 has rotated such that its α-amino group is
within hydrogen bond distance to the backbone carbonyl group of Tyr 397 and the hydroxyl
group of Thr 398. A nearly identical placement of acivicin is observed in both active sites.
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Figure 5. The C-terminus is ordered in the acivicin-modified HpGT structure
A ribbon stereodiagram of HpGT is shown with the 40 kDa subunit colored in purple and the
20 kDa subunit in green. Relevant active site residues are shown in ball and stick representation.
Carbon atoms are colored in green (20 kDa subunit), purple (40 kDa subunit), grey (acivicin)
and yellow (the ordered C-terminus). Oxygen atoms are shown in red and nitrogen atoms in
blue. In each of the previously determined HpGT structures, residues Lys 565, Glu 566, and
Phe 567 were disordered. In the acivicin-modified HpGT structure, unambiguous electron
density corresponding to the C-terminus of the protein was observed (not shown). Residues
Arg 175 and Arg 475 appear to stabilize this region, positioning Phe 567 over the catalytic
nucleophile, Thr 380.
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Figure 6. The truncated C-terminus of HpGT is unique among
γ-glutamyltranspeptidases. (A) An alignment of representative γ-glutamyltranspeptidase
sequences indicates that an aromatic residue is typically found at the C-terminal position. HpGT
is considerably shorter than other γ-glutamyltranspeptidases, suggesting that the active site
capping by Phe 567 observed in the acivicin-modified HpGT structure may be unique among
γ-glutamyltranspeptidases. Sequences used in the alignment are H. pylori (O25743), E. coli
(P18956), H. sapiens (P19440), D. rerio (Q7T2A1), D. melanogaster (Q9VWT3), C.
elegans (Q9N5V4), A. thaliana (Q8VYW6), and S. cerevisiae (Q05902). (B) The
superimposed structures of HpGT and E. coli γGT are shown in ribbon representation. HpGT
is colored as in Figure 4 and the 40 kDa and 20 kDa subunits of E. coli γGT are colored in blue
and grey respectively. Whereas the C-terminus of HpGT (yellow) extends over the active site,
the C-terminus of E. coli γGT reverses and extends back to the surface of the protein, creating
a more open active site pocket.
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Figure 7. An extensive hydrogen bond network in the C-terminal region of the 20 kDa subunit of
HpGT is required for autoprocessing and catalytic activity
In the stereodiagrams, a ribbon illustration of HpGT is presented with relevant residues shown
in ball and stick representation. Atoms are colored as in Figure 4 and potential hydrogen bonds
were identified with Chimera (indicated as solid black lines). Gly 472 and Gly 473, whose
backbone amides form the proposed oxyanion hole, are highlighted as a red ribbon. (A) Arg
475 is critical for positioning of both the Tyr 433 loop and the Phe 567 C-terminal tail, as well
as the backbone amides of Gly 472 and Gly 473. (B) The Glu 515/Arg 564 and the Asp 562/
Arg 502 salt bridges stabilize the active site region and are critical for autoprocessing and
enzymatic activity. Arg 513 also contributes to the overall integrity of the active site.
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Table 1
Data collection and refinement statistics for the acivicin-modified H.pylori γ-
glutamyltranspeptidase structure
Data collection statistics
Space group P21
Cell Dimensions (Å) 54.7, 105.4, 91.9, β=91.7
Resolution 29.2–1.70 Å (1.76–1.70 Å)
Number of unique reflections 110177
Average Redundancy 3.3 (3.3)
<I/σI> 23.3 (1.6)
Completeness 96.5% (95.1%)
Rmerge 5.2% (64.1%)
Refinement statistics
Number of atoms 8687
 Protein atoms 8128
 Solvent atoms 737
 Ligand atoms 20
Rfactor 17.9% (23.2%)
Rfree 20.8% (27.9%)
Overall B factor 22.6 Å2
 Protein B factor 14.3 Å2
 Solvent B factor 27.7 Å2
 Acivicin B factor 29.8 Å2
RMSD from ideal values
 Bond lengths 0.013 Å
 Bond angles 1.45°
Estimated coordinate error 0.073 Å
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Table 2
Apparent kinetic constants for wild-type and mutant HpGT.
Hydrolysis Processing
Enzyme Km GNA(μM) Vmax (μmol/min/mg) t1/2 (minutes)
HpGT 22.1 ± 1.4 5.18 ± 0.08 49.3 ± 5.3
R175L 9.5 ± 0.9 0.77 ± 0.02 47.7 ± 4.0
R475L 2.9 ± 0.5 0.062 ± 0.003 45.6 ± 3.1
R502L N/A N/A No processing
R502L-Duet 5.0 ± 0.3 0.068 ± 0.001 N/A
R513L 3.8 ± 0.3 0.28 ± 0.01 227 ± 16
E515Q N/A N/A No processing
E515Q-Duet 2.7 ± 0.2 0.025 ± 0.001 N/A
F567A 15.9 ± 1.8 0.44 ± 0.01 27.1 ± 4.8
F567Stop 17.3 ± 2.4 0.43 ± 0.02 34.5 ± 3.3
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